Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune⦠read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
$2.69
Price+8.91%
$0.22
$161.082m
Small
4.1x
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$192k
-
1y CAGR-
3y CAGR-
5y CAGR$14.643m
-
1y CAGR-
3y CAGR-
5y CAGR-$1.30
-
1y CAGR-
3y CAGR-
5y CAGR$50.334m
$144.909m
Assets$94.575m
Liabilities$803k
Debt0.6%
-
Debt to EBITDA-$64.529m
-
1y CAGR-
3y CAGR-
5y CAGR